Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

AIDS

Volumn 14, Issue 18, 2000, Pages 2857-2867

  Miller, Veronica ^a   Sabin, Caroline ^b   Hertogs, Kurt ^c   Bloor, Stuart ^d   Martinez Picado, Javier ^e,f   D'Aquila, Richard ^e   Larder, Brendan ^d   Lutz, Thomas ^a   Gute, Peter ^a   Weidmann, Eckhart ^a   Rabenau, Holger ^a   Phillips, Andrew ^b   Staszewski, Schlomo ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Virco BVBA   (Belgium)

^d Virco UK Ltd   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Resistance; Salvage therapy; Shift to wild type; Treatment interruption

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD;

EID: 0034523865     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012220-00007     Document Type: Article

References (32)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
2. Antiretroviral therapy in adults: Updated recommendations of the international AIDS Society-USA Panel
3. CD4 cell count in HIV-1-infected individual remaining viraemic with highly active antiretroviral therapy (HAART)
4. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens in patients with human immunodeficiency virus infection
5. Prognostic value of virus load levels in patients receiving HAART: The Frankfurt HIV-Cohort
6. Delayed immunologic deterioration among patients who virologically fail protease inhibitor-based therapy
7. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
8. Replicative fitness of prolease inhibitor-resistant mutants of human immuno-deficiency virus type 1
9. Increased fitness of drug resistant HIV-1 prolease as a result of acquisition of compensatory mutations during suboptimal therapy
10. Loss of Tamivudine resistance in a zidovudine and tamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro tamivudine drag pressure
11. Genotypic or phenotypie susceptibility testing may not predict clinical responses to indinavir
12. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
13. Patterns of resistance and cross-resistance to HIV-1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor Ioviride
14. Baseline resistance and virological response to Mega-HAART salvage therapies
15. Rapid decline in delectability of HIV-1 drug resistance mutations after stopping therapy
16. Clonal sequencing for detection of resistance mutations and their linkage
17. CD4 lymphocyte count as a predictor of the duration of HAART-induced suppression of HIV-1 virus load
18. Virological response to protease inhibitor therapy in an HIV clinical cohort
19. A rapid method for simultaneous detection of phenotpyic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV-1 isolales of patients treated wilh antiretroviral drugs (PR-RT Antivirogram)
20. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multi-nucleoside analog resistance
21. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing
22. A novel method for site-directed mutagenesis using PCR and uracil DANN glycosylase
23. Resistance profile of HIV-1 RT inhibitor abacavir (ABC, 1592U89) after monotherapy and combination therapy
24. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure
25. Association of viral load, CO4 cell count, and treatment with clinical progression in HIV patients with very low CD4 cell counts: The EuroSIDA Cohort
26. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
27. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral aclivity and correlation of baseline phenotypic drug susceptibility with virologic outcome
28. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372)
29. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
30. Drug resistance and short term virological response in patients prescribed multidrug rescue therapy
31. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV Cohort